PRFX - PAINREFORM LTD.

2.41
-0.080   -3.320%

Share volume: 5,603
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$2.49
-0.08
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-8.71%
1 Month
9.55%
3 Months
215.32%
6 Months
84.67%
1 Year
3.88%
2 Year
181.21%
Key data
Stock price
$2.41
P/E Ratio 
0.00
DAY RANGE
$2.38 - $2.52
EPS 
N/A
52 WEEK RANGE
$0.58 - $3.71
52 WEEK CHANGE
$2.55
MARKET CAP 
1.567 M
YIELD 
N/A
SHARES OUTSTANDING 
7.026 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$20,420
AVERAGE 30 VOLUME 
$1,397,672
Company detail
CEO: Ilan Hadar
Region: US
Website: painreform.com
Employees: 4
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

PainReform Ltd. engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair.

Recent news